Adherex Technologies Inc. (NASDAQ:FENC) Receives Average Rating of "Moderate Buy" from AnalystsMarket Beat·Jul 10 at 03:29 AMFENC+2.69%
Fennec Pharma former director Rosty Raykov disposes of 9,599 common shares for $99,926.59PUBT·Jul 2 at 03:06 PMFENC+2.69%
Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record QuarterMarket Beat·May 23 at 09:05 AMFENC+2.69%
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting | FENC Stock NewsStockTitan·May 21 at 09:01 AMFENC+2.69%
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FENC Stock NewsStockTitan·May 18 at 07:30 AMFENC+2.69%
Fennec Pharma | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 15.11 MEarnings Watch·May 14 at 03:38 PMFENC+2.69%
Fennec Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcriptbenzinga_article·May 14 at 08:32 AMFENC+2.69%
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026 | FENC Stock NewsStockTitan·May 6 at 09:36 PMFENC+2.69%LABU+7.13%
